Journals / International Journal of Medical Biochemistry / 2021 / Cilt: 4 - Sayı: 2

Biosafety risk assessment of a clinical biochemistry laboratory for SARS-CoV2 infection

Pages
104–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In laboratories, risk assessment is recommended at predetermined periods and in the event of new circumstances.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Clinical laboratories are a transfer point for infected patient samples.
📊
Key Findings & Data:On February 12, 2020, the WHO published an interim guidance document, "Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV)" and it was highly recommended that all coronavirus 2019 (COVID-19) testing procedures be performed based on a local risk assessment.
💡
Conclusion & Impact:In laboratories, risk assessment is recommended at predetermined periods and in the event of new circumstances.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Clinical laboratories are a transfer point for infected patient samples. According to the World Health Or ganization (WHO) Laboratory Biosafety Guideline, a risk assessment approach is the backbone of laboratory biosafety. In laboratories, risk assessment is recommended at predetermined periods and in the event of new circumstances. On February 12, 2020, the WHO published an interim guidance document, "Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV)" and it was highly recommended that all coronavirus 2019 (COVID-19) testing procedures be performed based on a local risk assessment. This study was designed to evaluate the biosafety risk in a biochemistry laboratory where routine testing of patients diagnosed with COVID-19 is performed. Methods: Risk assessment for tests performed on analyzers and a complete urinalysis was performed using the risk assessment template included in the subsequent WHO interim guidance document, “Laboratory biosafety guidance related to coronavirus disease (COVID-19).” Results: The overall initial risk for tests performed on analyzers and a complete urinalysis test was determined to be very high. Processes such as pipetting a sample and checking a sample tube by scanning the barcode during tests performed on analyzers were suspended until additional risk control measures could be implemented. The manual microscopic urinalysis process was also discontinued. To reduce the risk, surgical masks, surgical caps, eye protection, and disposable laboratory coats were added to the previously mandated personal protective equipment. After imple menting additional risk control measures, the total residual risk of both processes was graded medium. Conclusion: Since there is as yet no effective treatment for COVID-19, exposure risk is considered severe. Therefore, the probability of exposure is important in determining the level of risk. Measures put in place reduced the total residual risk.

🔖

Cite This Article

ZORBOZAN, N., ZORBOZAN, O. (2021). Biosafety risk assessment of a clinical biochemistry laboratory for SARS-CoV2 infection. International Journal of Medical Biochemistry, Cilt: 4 - Sayı: 2, 104–120. https://ajindex.com/articles/406975

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270–3
  2. WHO. Coronavirus disease 2019 (COVID-19) situation report–52. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4. Accessed Mar 15, 2021
  3. Republic of Turkey Ministry of Health. Coronavirus is not stronger than the measures we will take. Available at: www.saglik. gov.tr/EN,64527/quotcoronavirus-is-not-stronger-than-themeasures-we-will-takequot.html. Accessed Mar 11, 2020
  4. Schröder I. COVID-19: a risk assessment perspective. ACS Chem Health Saf 2020;27(3):160–9
  5. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARSCoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ 2020;369:m1443
  6. WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. Interim guidance. Available at: https://www.who.int/publications/i/item/10665-331501. Accessed Sep 1, 2020
  7. Mesoraca A, Margiotti K, Viola A, Cima A, Sparacino D, Giorlandino C. Evaluation of SARS-CoV-2 viral RNA in fecal samples. Virol J 2020;17(1):86
  8. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv. 2020 Mar 8. Doi: https://doi.org/10.1101/2020.03.05.20030502. [Epub ahead of print]
  9. Jeong HW, Kim SM, Kim HS, Kim YI, Kim JH, Cho JY, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin Microbiol Infect 2020;26(11):1520–4
  10. Iwen PC, Stiles KL, Pentella MA. Safety considerations in the laboratory testing of specimens suspected or known to contain the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Am J Clin Pathol 2020;153(5):567–70
  11. WHO. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19): interim guidance, 12 February 2020. Available at: https://apps.who.int/iris/handle/10665/331138. Accessed Mar 1, 2020
  12. Centers for Disease Control and Prevention (CDC). Interim guidelines for collecting, handling, and testing clinical specimens from persons for Coronavirus disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-nCoV/ lab/guidelines-clinical-specimens.html. Acc